Andrews Alliance and Waters Sign Co-Marketing Agreement
Firms to Co-Market New Semi-Automated Sample Preparation Approach for Protein Therapeutics Glycosylation Profiling
WALTHAM, Massachusetts, June 15, 2017 /PRNewswire/ -- Andrew Alliance and Waters Corporation (NYSE: WAT) announced they have signed an agreement that will bring drug development scientists an easy-to-use, semi-automated sample preparation approach for released N-glycan profiling and analysis by LC and LC-MS. Under the co-marketing agreement, Waters will combine its existing Glycoworks™ RapiFluor-MS™ (RFMS) N-Glycan Kits with an Andrew pipetting robot that will allow laboratories to meet the demands on them for glycan profiling while improving the accuracy and precision of LC and LC-MS results.
Video - https://www.youtube.com/watch?v=FBWJUFAVwPk
Piero Zucchelli, CEO and Founder of Andrew Alliance, stated, "The Waters Glycoworks RapiFluor-MS N-Glycan Kit offers strategic and critical value that should not be compromised by the uncertainty induced by manual sample pipetting. The use of the Andrew robot for unattended execution of the kit's sample preparation workflow addresses this point, and enables scientists to make decisions based on solid and reproducible data."
"With the number of protein therapeutics in development, the demand for glycan analyses is growing exponentially every year, no question about it. The combination of the Andrew robot with Waters RapiFluor-MS N-Glycan Kit is an ideal solution for laboratories managing larger volumes of released N-glycan analyses," said Dr. Jeff Mazzeo, Vice President of Marketing. "RFMS simplified sample preparation and, now, by combining it with the Andrew robot, automating the protocol has never been easier."
Most biotherapeutic proteins available on the market today are glycoproteins. The heterogeneous sugar molecules, or glycans, on these proteins affect the potency, stability, and therapeutic safety profiles of these drugs. As a result, biopharmaceutical companies must provide detailed structural information on these glycans when submitting new applications to regulatory authorities and must monitor them throughout the manufacturing process.
Since the launch of the GlycoWorks RapiFluor-MS N-Glycan Kit in February of 2015, laboratories worldwide have seen the benefits of simplified sample preparation and achieved unprecedented levels of sensitivity and speed.
The combination of Waters and Andrew Alliance technologies takes released N-glycan sample preparation to the next level by making it simpler and more efficient to scale up samples tested with the same enhanced optical and MS sensitivity users have experienced with the RapiFluor-MS labelling reagent. Semi-automation of released N-glycans is now affordable and easily accessible.
For more information about the GlycoWorks RapiFluor-MS N-Glycan Kit, visit www.waters.com/glycans.
About Andrew Alliance (www.andrewalliance.com)
Andrew Alliance S.A. is an independent privately financed company, based in Geneva (Switzerland) Boston (USA) and Paris (France). The company is a worldwide leader in robotics for life science, and provides innovative solutions like Andrew, the liquid handling robot that uses standard manual pipettes, that allow scientists to focus on their core competencies.
About Waters Corporation (www.waters.com)
Waters Corporation develops and manufactures advanced analytical and material science technologies for laboratory dependent organizations. For more than 50 years, the company has pioneered a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis systems.
Waters, Glycoworks, RapiFluor-MS are trademarks of Waters Corporation. Andrew Alliance is a trademark of Andrew Alliance SA.
Media Contact:
Scott Roler
Scott.roler@andrewalliance.com
Share this article